Special Collections by Oncotarget: Skin Cancer & Melanoma

As the summer months begin, Oncotarget launches a new Special Collection of scientific publications directly related to skin cancer and melanoma research.

BUFFALO, NY-June 4, 2021 – Skin cancer is a highly preventable cancer (in non-hereditary cases), due to a major risk factor being prolonged exposure to ultraviolet (UV) radiation. However, skin cancer is the most commonly diagnosed cancer in the United States. Predictions show that one in five Americans will be diagnosed with skin cancer by the age of 70. 

Melanoma of the skin is the most serious type of skin cancer due to its tendency to spread to other organs. Surprisingly, as much as 30% of all melanoma cases are a result of factors other* than exposure to the sun or other UV light. The causes of such cases are still unknown to researchers, but some suggest that causes may be hereditary.

Papers within Oncotarget’s new Special Collection on Skin Cancer & Melanoma relate to various topics on skin cancer research, including a 2018 paper from Australia on the first blood test for early detection of melanoma, a paper by researchers from Columbia University on a combined therapeutic approach that improves anti-tumor antibody therapy in melanoma, and many more.

This Special Collection is intended to be a tool for researchers and science readers alike to learn more about the current landscape of skin cancer. The creators of these collections are hopeful that this resource may help researchers discover new biomarkers, mechanisms, and therapies that lead to enhanced treatments for cancer and improve our collective quality of life.

Click here to read Oncotarget’s Special Collection on Skin Cancer & Melanoma.

Follow Oncotarget on social media: 

Twitter – https://twitter.com/Oncotarget 

Facebook – https://www.facebook.com/Oncotarget 

YouTube – www.youtube.com/c/OncotargetYouTube 

LinkedIn – https://www.linkedin.com/company/oncotarget/ 

Pinterest – https://www.pinterest.com/oncotarget/ 

Instagram – https://www.instagram.com/oncotargetjrnl/ 

About Impact Journals (Oncotarget’s publisher):

Impact Journals is an open-access publisher with a mission to provide scientists with the opportunity to share their exceptional discoveries, offer services that enable rapid dissemination of results, and to present vital findings from the many fields of biomedical science. Our goal is life without disease.

Impact Journals 

Impact Journals LLC

6666 E.Quaker St. Ste. 1 

Orchard Park, NY 14127

—

Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.

For media inquiries, please contact media@impactjournals.com.